A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
- PMID:32796842
- PMCID: PMC7427994
- DOI: 10.1038/s41467-020-17972-1
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
Abstract
The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.
Conflict of interest statement
The authors declare no competing interests.
Figures



References
- WHO. Draft landscape of COVID-19 candidate vaccines–15 July 2020.https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand.... Accessed 19 July 2020.
- van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.Nature, 10.1038/s41586-020-2608-y (2020). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous
